Form 8-K - Current report:
SEC Accession No. 0001193125-23-081417
Filing Date
2023-03-28
Accepted
2023-03-28 08:01:29
Documents
12
Period of Report
2023-03-28
Items
Item 8.01: Other Events
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K d483501d8k.htm   iXBRL 8-K 31011
  Complete submission text file 0001193125-23-081417.txt   158998

Data Files

Seq Description Document Type Size
2 XBRL TAXONOMY EXTENSION SCHEMA aneb-20230328.xsd EX-101.SCH 2838
3 XBRL TAXONOMY EXTENSION LABEL LINKBASE aneb-20230328_lab.xml EX-101.LAB 18737
4 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE aneb-20230328_pre.xml EX-101.PRE 11699
6 EXTRACTED XBRL INSTANCE DOCUMENT d483501d8k_htm.xml XML 3529
Mailing Address 1415 RANCH ROAD 629 SOUTH, SUITE 201 LAKEWAY TX 78734
Business Address 1415 RANCH ROAD 629 SOUTH, SUITE 201 LAKEWAY TX 78734 737 203 5270
Anebulo Pharmaceuticals, Inc. (Filer) CIK: 0001815974 (see all company filings)

IRS No.: 851170950 | State of Incorp.: DE | Fiscal Year End: 0630
Type: 8-K | Act: 34 | File No.: 001-40388 | Film No.: 23766225
SIC: 2834 Pharmaceutical Preparations